treatment-resistant depression
Articles tagged with “treatment-resistant depression”
Boston Clinics Spotlight Ketamine's Mental Health Role
Boston health clinics are expanding ketamine therapy for depression and PTSD — here's what it means for patients exploring oral ketamine tablets.
One Patient's Year With Ketamine and Experimental Care
A Guardian journalist tried ketamine and other cutting-edge depression treatments for a year. What oral ketamine patients can learn from her experience.
How Symptom Tracking Reshapes Oral Ketamine Dosing for TRD
Regular symptom tracking and faster dose adjustments drive TRD remission sooner. Here's what that means for oral ketamine tablet users.
NMDA Antagonist Side Effects: What Tablet Users Need to Know
New clinical data on NMDA antagonist side effects and dropout rates has real implications for oral ketamine tablet users. Here's what the research means for you.
Why Patients Quit Ketamine Early—And How Tablets Factor In
New clinical data on NMDA antagonist dropout rates reveals how side effect management and route of administration affect treatment-resistant depression outcomes.
TRD Guidelines Spotlight Ketamine's Growing Role
Psychiatric Times highlights optimizing TRD treatments in 2026. Here's what it means for patients using oral ketamine tablets for depression.
Oral Ketamine Side Effects: What New TRD Data Tells Us
New clinical guidance on NMDA antagonist side effects and discontinuation rates offers key lessons for oral ketamine tablet users managing treatment-resistant depression.
NMDA Antagonist Side Effects: What Tablet Users Should Know
New research in Psychiatric Times breaks down side effect profiles and discontinuation rates for NMDA antagonists — here's what it means for oral ketamine tablet users.
Ketamine Side Effects & Dropout Rates: What Data Says
New analysis in Psychiatric Times urges data-driven ketamine dosing. Here's what the side-effect and dropout data means for oral tablet users.
Glutamate Pathway Treatments Reshape TRD Care in 2026
New research highlights how glutamate-targeting drugs like esketamine and ketamine are reshaping treatment-resistant depression care. Here's what it means for oral ketamine users.
Faster TRD Remission: What Dose Optimization Means
New clinical guidance on TRD care emphasizes rapid dose adjustment and symptom tracking — here's what it means for oral ketamine tablet patients.
Glutamate Pathway Treatments Reshaping TRD Care
New research highlights glutamate-based therapies like esketamine and ketamine tablets for treatment-resistant depression. Here's what it means for oral ketamine users.
Insurance Gaps Push Patients Toward Oral Ketamine
Most insurers still deny ketamine coverage in 2026. Here's what the access gap means for patients exploring oral ketamine tablets as an affordable option.
How Doctors Choose TRD Treatments in 2026
Clinicians weigh patient preference, speed of action, and access when choosing TRD treatments. Here's what that means for oral ketamine tablet patients.
Esketamine for Treatment-Resistant Depression in 2026
Clinicians are increasingly turning to esketamine for TRD and suicidal ideation. Here's what it means for oral ketamine tablet users in 2026.
Glutamate Pathway Drugs Are Reshaping TRD Care
New research highlights how glutamate-targeting drugs like esketamine and oral ketamine are changing treatment-resistant depression care in 2026.
Why Remission—Not Just Relief—Changes Ketamine Care
New clinical guidance pushes beyond symptom reduction toward full remission in TRD. Here's what that means for oral ketamine tablet users.
Ketamine's Role in Treatment-Resistant Depression Care
Psychiatric Times highlights ketamine among top TRD approaches. Here's what oral ketamine tablet users need to know about access and dosing.
BPL-003 Shows Sustained TRD Relief in Phase 2a Trial
Beckley Psytech's BPL-003 phase 2a part 2 data shows lasting symptom reduction in treatment-resistant depression — what it means for the TRD landscape.
Contact Ketamine Tablet
Send corrections, provider questions, or advertising inquiries.